Idelalisib

BNF:

8.1.5

Status:

Do Not Prescribe (DNP), Red

Decision Date:

None

Comments

RED¹: NICE TA359: For treating chronic lymphocytic leukaemia. (decision date - November 2015)

DO NOT PRESCRIBE (DNP)^6: NICE TA328 - follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (decision date - January 2015)

DO NOT PRESCRIBE (DNP)⁶ :NICE TA469 - idelalisib with ofatumumab for treating chronic lymphocytic leukaemia. (Terminated appraisal) (Decision date  - September 2017)

DO NOT PRESCRIBE (DNP)⁶: NICE TA604 - treating refractory follicular lymphoma. (Decision date - November 2019)

NHS England drug. To be used in line with NHS England commissioning intentions

Black Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating

search again